Yahoo
NasdaqCM - Delayed Quote USD

Amarin Corporation plc (AMRN)

12.11 -0.63 (-4.91%)
At close: October 30 at 4:00:02 PM EDT
Trade AMRN on Coinbase
Chart Range Bar
Loading chart for AMRN
  • Previous Close 12.73
  • Open 12.71
  • Bid 10.43 x 100
  • Ask 14.41 x 100
  • Day's Range 12.00 - 12.73
  • 52 Week Range 11.25 - 17.31
  • Volume 100,025
  • Avg. Volume 68,642
  • Market Cap (intraday) 509.133M
  • Beta (5Y Monthly) 0.77
  • PE Ratio (TTM) --
  • EPS (TTM) -0.80
  • Earnings Date Oct 28, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 13.00
  • Zacks Rating Neutral

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

www.amarincorp.com

80

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/1/2026, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

AMRN
10.36%
MSCI WORLD (^990100-USD-STRD)
9.75%

1-Year Return

AMRN
25.66%
MSCI WORLD (^990100-USD-STRD)
10.75%

3-Year Return

AMRN
13.50%
MSCI WORLD (^990100-USD-STRD)
73.81%

5-Year Return

AMRN
87.31%
MSCI WORLD (^990100-USD-STRD)
52.40%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 39.55M
Earnings 245k
Profit Margin 0.62%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
20M
40M
-20.0%
-15.0%
-10.0%
-5.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

13.00
13.00 Average
12.11 Current
13.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/25/2025
Analyst Goldman Sachs
Rating Action Maintains
Rating Sell
Price Action Raises
Price Target 7 -> 12

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -10.87%

  • Return on Assets (ttm)

    -2.38%

  • Return on Equity (ttm)

    -4.24%

  • Revenue (ttm)

    176.11M

  • Net Income Avi to Common (ttm)

    -19.14M

  • Diluted EPS (ttm)

    -0.80

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    323.38M

  • Total Debt/Equity (mrq)

    1.71%

  • Levered Free Cash Flow (ttm)

    39.86M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: